[Click eStock] 'Newly Listed' Baizencell, an Immunocyte Therapy Specialist with Three Platforms

[Asia Economy Reporter Lee Seon-ae] Shinhan Financial Investment evaluated Baizencell, which is newly listed on the 25th, as a specialized immunocyte therapy company possessing three platforms.

The platforms consist of ViTier: antigen-specific CTL (cytotoxic T lymphocyte) autologous cell therapy, ViRanger: gamma delta T cell allogeneic cell therapy, and ViMedier: umbilical cord blood-derived MDSC (myeloid-derived suppressor cell) allogeneic cell therapy.

ViTier's VT-EBV-N is currently undergoing a Phase 2 clinical trial related to NK/T lymphoma. VT-Tri(1)-A is in Phase 1 clinical trial for AML, and ViMedier's VM-GD has received IND approval for Phase 1/2a clinical trial for GvHD, with clinical trials expected to commence.

VT-EBV-N is in Phase 2 clinical trial as an adjuvant therapy for patients with extranodal NK/T lymphoma in CR status. The trial is a double-blind, placebo-controlled study involving 48 patients. Patients will be followed up for 2 years post-treatment, with the primary endpoint being DFS and the secondary endpoint OS. For reference, in an investigator-initiated clinical trial conducted from 2007 to 2015, 10 patients showed a 90% 5-year long-term relapse-free survival rate. Early commercialization through conditional approval is expected after the Phase 2 trial completion. Marketability will be expanded through indication extension after approval.

ViRanger's gamma delta T cells and ViMedier's MDSC are held as allogeneic cell therapy platforms. Both platforms are technologies capable of global partnership agreements depending on development progress. ViTier's VR-CAR plans to develop a solid tumor treatment by expressing CAR on allogeneic gamma delta T cells. In 2022, domestic and international patents were filed for the CAR structure, and publication of preclinical results for VR-CAR is targeted. ViMedier's MDSC, VM-GD, is expected to enter domestic Phase 1/2a clinical trials for GvHD (graft-versus-host disease), which currently has no standard treatment, within the year. Researcher Jang Se-hoon of Shinhan Financial Investment explained, "IND approval was obtained domestically in 2020, marking the world's first MDSC clinical trial," adding, "Indication expansion to atopic dermatitis, which has a large market size, is expected thereafter."

This content was produced with the assistance of AI translation services.